生物康生物公司在与詹森生物技术公司解决专利纠纷后,确保其Stelara生物类似药在欧洲,英国,加拿大和日本的市场进入. Biocon Biologics secures market entry for its Stelara biosimilar in Europe, UK, Canada, and Japan after resolving patent disputes with Janssen Biotech.
Biocon Biologics，Biocon Ltd的子公司，在与Janssen Biotech Inc.、Janssen Sciences Ireland和Johnson & Johnson签署了和解和许可协议后，确保了其生物仿制药Stelara在欧洲、英国、加拿大和日本的市场准入。 Biocon Biologics, a Biocon Ltd subsidiary, secures market entry for its biosimilar to Stelara in Europe, the UK, Canada, and Japan after signing a settlement and license agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson. 该协议解决了专利争端,并为Bmab 1200商业化铺平了道路。 Bmab 1200与Stelana建议的生物相似,后者治疗自发免疫疾病。 The agreement resolves patent disputes and paves the way for commercialization of Bmab 1200, a proposed biosimilar to Stelara, which treats autoimmune diseases. 该公司旨在为受自发免疫疾病影响的病人提供负担得起和有效的治疗选择。 The company aims to provide affordable and effective treatment options for patients affected by autoimmune diseases.